Oral vaccine study probes gut barrier changes in healthy volunteers

NCT ID NCT04083950

Ongoing Knowledge-focused Sponsor: USDA, Western Human Nutrition Research Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether taking an oral typhoid vaccine temporarily makes the gut more 'leaky' and how the immune system responds. Ten healthy adults will receive the vaccine and a low-dose aspirin challenge. Researchers will measure sugar levels in urine and immune cells in blood to track changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ty21a typhoid oral vaccine (Vivotif) and aspirin
What this could lead to: If successful, this could help researchers understand how oral vaccines affect the gut barrier, potentially improving vaccine design.
What could go wrong: This is a very small, early-phase study with only 10 participants, so results may not apply broadly. The vaccine is known to be safe but may cause mild digestive upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation inflammatory disease typhoid fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATION INTESTINAL PERMEABILITY TYPHOID FEVER VACCINE

Contacts and locations

Locations

USDA, ARS, Western Human Nutrition Research Center

Davis, California, 95616, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.